1 day Ago By Defense World Staff
Commonwealth Equity Services LLC raised its position in shares of Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR – Free Report ) by 3.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.
The firm owned 34,663 shares of the biotechnology company’s stock after acquiring an additional 1,250 shares during the period. Commonwealth Equity Services LLC’s holdings in Arrowhead Pharmaceuticals were worth $901,000 at the end of the most recent reporting period. Other institutional investors have also recently added to or reduced their stakes in the company.
Vanguard Group Inc. grew its position in Arrowhead Pharmaceuticals by 16.2% during the first quarter.
Vanguard Group Inc. now owns 12,404,050 shares of the biotechnology company’s stock valued at $354,756,000 after acquiring an additional 1,731,974 shares during the period. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $40,451,000.
Goldman Sachs Group Inc. grew its position in Arrowhead Pharmaceuticals by 136.6% during the fourth quarter.
Goldman Sachs Group Inc. now owns 1,061,967 shares of the biotechnology company’s stock valued at $32,496,000 after acquiring an additional 613,067 shares during the period. Eventide Asset Management LLC purchased a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at about $9,587,000.
Finally, American International Group Inc. grew its position in Arrowhead Pharmaceuticals by 13.4% during the first quarter.
American International Group Inc. now owns 220,217 shares of the biotechnology company’s stock valued at $6,298,000 after acquiring an additional 26,009 shares during the period. Hedge funds and other institutional investors own 62.
61% of the company’s stock. Arrowhead Pharmaceuticals Stock Performance NASDAQ:ARWR opened at $20.01 on Wednesday.
Arrowhead Pharmaceuticals, Inc. has a one year low of $19.44 and a one year high of $39.
83. The business’s 50-day simple moving average is $25.15 and its 200 day simple moving average is $25.
61. The stock has a market cap of $2.49 billion, a price-to-earnings ratio of -4.
83 and a beta of 0.96. Wall Street Analyst Weigh In Several brokerages have recently weighed in on ARWR.
Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. B. Riley reaffirmed a “buy” rating and issued a $55.
00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, August 1st.
Chardan Capital reaffirmed a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 17th. Finally, The Goldman Sachs Group began coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th.
They issued a “neutral” rating and a $31.00 target price for the company. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company.
According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $44.25.
Get Our Latest Stock Report on ARWR Insider Buying and Selling at Arrowhead Pharmaceuticals In other news, insider Tracie Oliver sold 9,394 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total transaction of $237,480.
32. Following the sale, the insider now directly owns 127,107 shares in the company, valued at approximately $3,213,264.96.
The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . 4.50% of the stock is currently owned by insiders.
Arrowhead Pharmaceuticals Company Profile ( Free Report ) Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. Recommended Stories Five stocks we like better than Arrowhead Pharmaceuticals 2 Fintech Stocks to Buy Now and 1 to Avoid Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? 3 Must-Buy Warren Buffett Stocks for Volatile Times Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What is Insider Trading? What You Can Learn from Insider Trading Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
